{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.142"}]}],"title":"Muscle weakness right-sided (Grade 3)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.142"}]}],"title":"Stridor (Grade 3)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.142"}]}],"title":"Vagus nerve disorder (Grade 3)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.142"}]}],"title":"Gait disturbance (Grade 3)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.142"}]}],"title":"Neutrophil count decreased (Grade 3)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"Adverse events and clinically significant laboratory abnormalities which meet Grade 3, 4, or 5 criteria according to Common Terminology Criteria for Adverse Events (CTCAE) classified by investigators and treating physicians as related to study treatment (probable, possible, and definite) will be summarized by maximum intensity/grade. Adverse events will be graded according to CTCAE version 4.0.","groups":[{"description":"Participants receive panobinostat nanoparticle formulation MTX110 IT by CED infusion on day 1 or days 1 and 2 as determined by dose level. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.\n\nPanobinostat Nanoparticle Formulation MTX110: Given IT\n\nConvection-Enhanced Delivery (CED): Undergo CED","id":"OG000","title":"Phase 1: Treatment (MTX110)"}],"paramType":"NUMBER","populationDescription":"While individual participants were assigned to receive separate doses, participants are presented in one Arm/Group due to confidentiality concerns for this rare disease study","reportingStatus":"POSTED","timeFrame":"Up to 12 Months","title":"Proportion of Participants With Grade 3 or Higher, Treatment-related, Adverse Events","type":"PRIMARY","unitOfMeasure":"proportion of participants"}